Capitan Orthopedics Secures FDA Breakthrough Status for Shoulder Implant

Capitan Orthopedics has received breakthrough device designation from the U.S. Food and Drug Administration for its SupraSpacer implant, aimed at treating irreparable rotator cuff injuries.

Rotator cuff injuries affect more than two million people annually, with over 700,000 undergoing surgical repair. However, patients whose injuries cannot be addressed through conventional procedures often have limited treatment options—particularly younger individuals for whom reverse shoulder replacement may not be ideal.

The SupraSpacer implant is designed to restore shoulder joint alignment by supporting the joint internally and preventing upward movement of the humerus. This approach helps improve mobility and reduce pain while preserving the possibility of future surgical interventions if needed.

Developed for use in ambulatory surgical settings, the system includes sterile instruments and implants to streamline procedures. The breakthrough designation highlights the significant unmet need in this area and may accelerate the device’s development and regulatory pathway.

05-05-2026